Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Scientists identify new drug target for multiple tumour types

A research team headed by scientists at University of California San Diego School of Medicine and the Ludwig Institute for Cancer Research at UC San Diego has identified an enzyme involved in remodelling the plasma membrane of multiple cancer cell types that is critical to both survival of tumours and their uncontrolled growth.

The finding, published in the the journal Cell Metabolism, suggests a potential target for new drugs.

"Cancers are characterised not only by major changes in their genomes, but also by profound shifts in how they take up and utilise nutrients to propel rapid tumour growth," said senior author Paul S. Mischel, MD, professor in the UC San Diego School of Medicine Department of Pathology and Ludwig member. "How do these diverse aspects fit together and can they be taken advantage of, for the benefit of patients?"

In the study, conducted in collaboration with Benjamin Cravatt, PhD, professor at Scripps Research, and led by first author Junfeng Bi, PhD, in Mischel's lab, researchers identified an enzyme called LPCAT1, whose levels increase in cancer and which plays a key role in tumour growth by changing the phospholipid composition of the cancer cells' plasma membrane, allowing amplified and mutated growth factor signals to spur tumour growth.

Without LPCAT1, tumours cannot survive.

When researchers genetically depleted LPCAT1 in multiple types of cancer in mice, including highly lethal glioblastomas (brain) and an aggressive lung cancer, malignancies shrank dramatically and survival times improved.

The results, wrote the authors, demonstrate that LPCAT1 is an important enzyme that becomes dysregulated in cancer, linking common genetic alterations in tumours with changes in their metabolism to drive aggressive tumour growth.

"Advances in DNA sequencing technologies have reshaped our understanding of the molecular basis of cancer, suggesting a new and more effective way of treating cancer patients," said Mischel. "However, to date, precision oncology has yet to benefit many patients, motivating a deeper search into understanding how genetic alterations in tumours change the way cancer cells behave, and potentially unlocking new ways to more effectively treat patients."

"These results also suggest that LPCAT1 may be a very compelling new drug target in a wide variety of cancer types," Mischel concluded.

Source: University of California - San Diego

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation